Menkes Disease (MD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Menkes disease (MD) is a lethal multisystemic disorder of copper metabolism. The main manifestations are progressive neurodegeneration, connective tissue disturbances, and peculiar ‘kinky’ hair. MD is inherited as an X-linked recessive trait; as expected, most patients are men. MD is caused by mutations in the ATP7A gene, with most ATP7A mutations being intragenic or partial gene deletions. ATP7A is an energy-dependent transmembrane protein that transports copper to secreted copper enzymes and exports excess copper from cells. MD patients who are severely affected usually die before their third year of life. There is no cure for the disease, but very early copper-histidine treatment may alleviate some neurological symptoms.

·       Menkes disease (MD) is a rare condition with incidence estimates ranging from 0.75 to 1.27 cases per 100,000 live births in the USA. It is an inborn disorder of copper metabolism with multisystem ramifications.

Thelansis’s “Menkes Disease (MD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Menkes Disease (MD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Menkes Disease (MD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Menkes Disease (MD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Menkes Disease (MD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033